Recent clinical trials surrounding the medication Retatrutide , specifically the high-dose formulation ZPHC ZPHC, suggest a considerable impact on body mass decrease and associated metabolic illnesses . Researchers anticipate that this dual acting , influencing both GLP-1 and GIP pathways , has the potential to provide a major advance in the manage